2026 Global Healthcare Conference
Logotype for Fortrea Holdings Inc

Fortrea (FTRE) 2026 Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Fortrea Holdings Inc

2026 Global Healthcare Conference summary

25 Sep, 2026

Strategic direction and leadership changes

  • Recent acquisition of Worldwide Clinical Trials' clinical pharmacology and bioanalytical business aligns with a strategy to expand core capabilities and reduce reliance on third parties.

  • About 25%-30% of senior leaders are new, reflecting a significant management transition and a focus on growth.

  • The acquisition adds a 200-bed unit in San Antonio and a bioanalytical lab in Austin, enhancing capacity and operational control.

  • The company is shifting from post-spin stabilization to executing on new growth strategies.

  • New leadership emphasizes flipping the chapter from restructuring to growth and innovation.

Business model, operations, and market positioning

  • Clinical pharmacology is a differentiated, high-margin business, now with five sites and increased capacity for large studies.

  • The company is positioned to absorb growth with existing infrastructure, expecting operating leverage as service revenue grows.

  • Portfolio diversification is a priority, with a focus on higher-margin clinical pharmacology and FSO, and less emphasis on low-margin FSP.

  • Bookings rose nearly 20% in the first half, with a strengthening demand environment and a growing pipeline.

  • The company is gaining traction with new clients, including top 30 pharma and emerging biotechs, and expanding internationally, especially in China.

Technology, AI, and innovation

  • AI investments are focused on building a robust data layer and integrating intelligence into workflows through the FIT initiative.

  • Internal workflow improvements from AI are emerging, but external contracting and pricing changes related to AI are at least a year away.

  • FIT is being rolled out module by module, with pilots showing early success among clinical research associates.

  • ROI on AI investments is difficult to measure at this stage, but the company is keeping pace with industry peers.

  • The approach to AI is philosophical, aiming for long-term integration rather than standalone projects.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more